Mayo Clinic Florida
In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue giving them an experimental drug.
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that patients outside of cancer may not accept.
The Mayo Clinic-led team is now refining and prospectively testing its gene signature for personalizing gastric cancer treatment.
The 32-gene signature showed potential in predicting South Korean gastric cancer patients' overall survival and response to chemotherapy and immunotherapy.
At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.